Showing results (91-100 of 102) with videos related to
Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2016
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)Chris Karlovich, Jonathan W Goldman, Jong-Mu Sun, et al.Investigational New Drugs|May 9, 2019
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesotheliomaEmilie M J van Brummelen, Evgeny Levchenko, Manuel Dómine, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.Cancer Discovery|June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted TherapyAlexander Drilon, Manish R Sharma, Melissa L Johnson, et al.The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLCScott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.Pageof 11